drugset
drugset / Trial / NCT07382687

Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype

NCT07382687 ↗

Phase 3 Not yet recruiting 248 enrolled Fudan University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial. This study aims to investigate the efficacy and safety of Famitinib combination with SHR-A1811 in CDK4/6 inhibitors-resistent advanced HR+/HER2- breast cancer with SNF4 subtype.

Timeline

Start
2026-02-26
Primary completion
2028-12-31
Completion
2029-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Famitinib Small molecule 10 mg Oral
Comparator Trastuzumab Rezetecan Monoclonal antibody 4.8 mg/kg Intravenous

Indications

breast cancer